[Retracted] FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma

Table 2

Gene sets enriched in phenotype.

Gene set name	NES	NOM val	FDR val
High expression
KEGG_SMALL_CELL_LUNG_CANCER	1.82	0.001	0.112
KEGG_BASAL_CELL_CARCINOMA	1.72	0.002	0.194
KEGG_ERBB_SIGNALING_PATHWAY	1.65	0.016	0.280
KEGG_WNT_SIGNALING_PATHWAY	1.59	0.026	0.310
KEGG_PROSTATE_CANCER	1.51	0.042	0.355
GO_REGULATION_OF_EPIDERMIS_DEVELOPMENT	2.12	0.001	0.012
GO_KERATINOCYTE_PROLIFERATION	2.10	0.001	0.013
GO_EPIDERMIS_MORPHOGENESIS	2.07	0.001	0.014
GO_REGULATION_OF_EPIDERMAL_CELL_DIFFERENTIATION	2.04	0.001	0.015
GO_REGULATION_OF_KERATINOCYTE_DIFFERENTIATION	2.03	0.001	0.017
Low expression
KEGG_TYPE_I_DIABETES_MELLITUS	-1.82	0.015	0.275
KEGG_PRIMARY_IMMUNODEFICIENCY	-1.75	0.017	0.095
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS	-1.80	0.024	0.112
KEGG_ALZHEIMERS_DISEASE	-1.61	0.032	0.118
GO_CYTOPLASMIC_UBIQUITIN_LIGASE_COMPLEX	-2.15	0.001	0.031
GO_REGULATION_OF_B_CELL_DIFFERENTIATION	-1.96	0.001	0.409
GO_REGULATORY_T_CELL_DIFFERENTIATION	-1.80	0.008	0.335
GO_NEGATIVE_REGULATION_OF_PHAGOCYTOSIS	-1.78	0.009	0.262
GO_POSITIVE_REGULATION_OF_B_CELL_PROLIFERATION	-1.80	0.011	0.330

NES: normalized enrichment score; NOM: nominal; FDR: false discovery rate.